Study ID | Registry | Intervention | Control | aHR (I vs C) | Risk of bias |
All types of cancer | |||||
Wadstrom 2017 JAMA Intern Med31 | ARTIS | TCZ | csDMARDs | 0.9 (0.7; 1.2) | Low |
ABA | 0.9 (0.7; 1.1) | ||||
RTX | 0.9 (0.7; 1.0) | ||||
TNFi | 0.9 (0.9; 1.0) | ||||
Patients with history of cancer | |||||
Silva-Fernández 2016 Rheumatology (Oxford)30 | BSRBR-RA | TNFi | csDMARDs | 0.6 (0.4; 0.9) | Low |
RTX | 0.4 (0.1; 1.8) | ||||
Solid cancer (excluding NMSC) | |||||
Wadström 2017 JAMA Intern Med31 | ARTIS | TCZ | csDMARDs | 1.0 (0.7; 1.3) | Low |
ABA | 0.9 (0.7; 1.2) | ||||
RTX | 0.9 (0.8; 1.1) | ||||
TNFi | 0.9 (0.9; 1.0) | ||||
Non-melanoma skin cancer | |||||
Wadström 2017 JAMA Intern Med31 | ARTIS | TCZ | csDMARDs | 0.9 (0.4; 2.2) | Low |
ABA | 2.2 (1.3; 3.5) | ||||
RTX | 1.0 (0.7; 1.6) | ||||
TNFi | 1.1 (0.8; 1.4) | ||||
Melanoma | |||||
Wadström 2017 JAMA Intern Med31 | ARTIS | TCZ | csDMARD | <5 events | Low |
ABA | 1.4 (0.7; 3.1) | ||||
RTX | 0.7 (0.4; 1.4) | ||||
TNFi | 0.8 (0.6; 1.2) | ||||
Cervical cancer | |||||
Kim 2016 Arthritis Rheumatol26 | Claims database | bDMARDs | csDMARDs | 1.3 (0.9; 2.0) | High |
Wadström 2016 Ann Rheum Dis32 | ARTIS | TNFi | csDMARDs | 1.4 (0.6; 3.1) | Low |
Haematological cancer | |||||
Wadstrom 2017 JAMA Intern Med31 | ARTIS | TCZ | csDMARDs | <5 events | Low |
ABA | 1.0 (0.5; 2.0) | ||||
RTX | 0.7 (0.5; 1.2) | ||||
TNFi | 0.9 (0.7; 1.1) | ||||
Lymphoma | |||||
Mercer 2017 Ann Rheum Dis29 | BSRBR-RA | IFX | csDMARDs | 0.9 (0.4; 2.1) | Low |
ETA | 1.0 (0.5; 2.3) | ||||
ADA | 1.0 (0.5; 2.0) | ||||
All TNFi | 1.0 (0.6; 1.8) |
Additional details in online supplementary tables S32–59.
ABA, abatacept; ADA, adalimumab; aHR, adjusted HR; ARSTIS, anti-Rheumatic Treatment in Sweden Register; bDMARDs, biologic disease-modifying antirheumatic drugs; BSRBR, British Society of Rheumatology Biologics Register; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; ETA, etanercept; IFX, infliximab; RA, rheumatoid arthritis; RTX, rituximab; TCZ, tocilizumab; TNFi, tumour necrosis factor inhibitor; TOFA, tofacitinib.